- Home
- COCH vs TLPH Comparison
COCH vs TLPH Comparison
Compare COCH & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COCH | TLPH |
|---|---|---|
| Founded | 1995 | 2005 |
| Country | United States | United States |
| Employees | 47 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.7M | 42.3M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | COCH | TLPH |
|---|---|---|
| Price | $0.80 | $1.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 683.6K | 256.3K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,151,000.00 |
| Revenue This Year | $1.58 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.36 | $0.38 |
| 52 Week High | $1.89 | $1.57 |
Technical Indicators
Market Signals| Indicator | COCH | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 69.16 | 60.76 |
| Support Level | $0.64 | $1.01 |
| Resistance Level | $0.88 | $1.44 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 64.09 | 69.37 |
Price Performance
Historical ComparisonAbout COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.